Be the first person to write a business review for Afexa Life Sciences Inc.

Affymax, Inc. company was founded in 2001 and is based in Palo Alto, California. Affymax, Inc., a biopharmaceutical company, engages in the development of peptide-based drug candidates to enhance the treatment of serious and life-threatening conditions. The company’s lead product candidate, Hematide, is designed to treat anemia associated with chronic renal failure. Hematide is a synthetic peptide-based erythropoiesis stimulating agent designed to stimulate production of red blood cells. It is conducting Phase III clinical trials for the treatment of anemia associated with chronic renal failure, on dialysis, and pre-dialysis. Affymax has a license, manufacturing, and supply agreement with Nektar Therapeutics AL, Corporation to manufacture, develop, and commercialize Hematide.

Agencourt Biosciences uses more modern weapons to win its battles. The company provides genomic services (including DNA and whole genome sequencing) and nucleic acid purification products that help researchers improve the effectiveness of their drug development process. The company has teamed with a handful of international distributors and marketing partners to get its products into users' hands: These partners include Affymetrix and Life Technologies (formerly Invitrogen). Agencourt Biosciences is a subsidiary of Beckman Coulter.

Agennix develops oral, topical, and other forms of cancer treatments. The company's primary candidate, Talactoferrin, is an oral therapy in the late stages of development that is targeted to treat non-small cell lung cancer, a common and slow-growing type of lung cancer. Its other clinical development-stage candidates include therapies to treat tumors and prostate cancer, as well as non-cancerous conditions such as sepsis and diabetic foot ulcers. Agennix, which has offices in Munich, Germany; Princeton, New Jersey; and Houston, Texas, was formed in 2009 from the merger of Germany-based GPC Biotech AG and US-based Agennix Inc.

Aldagen's work stems from the need for tissue repair. The biopharmaceutical company develops cell regeneration therapies using adult stem cells. It uses a proprietary technology that isolates an enzyme known as aldehyde dehydrogenase, or ALDH, which it believes can target a number of diseases. Aldagen hopes its products will be used to treat hereditary metabolic diseases in children, leukemia, and cardiovascular diseases; all its drugs are in the development stage. The company does its own manufacturing and plans to do its own marketing. Venture capital firm Intersouth Partners holds about 42% of Aldagen, which filed an IPO in late 2009. The company is led by CEO W. Thomas Amick.

Alfacell Corporation was founded in 1981 and is headquartered in Somerset, New Jersey. Alfacell Corporation, a biopharmaceutical company, primarily engages in the discovery and development of a class of therapeutic drugs for the treatment of cancer and other pathological conditions. Its proprietary drug discovery and development program consists of therapeutics developed from amphibian ribonucleases. The company's lead drug product candidate, ONCONASE is evaluated in human clinical trials for the treatment of various forms of cancer. It also focuses on new drug application for unresectable malignant mesothelioma. In addition, the company completed a Phase I clinical trial for the treatment of non-small cell lung cancer.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.